SJS/TEN 2017: Building Multidisciplinary Networks to Drive Science and Translation

• Main Authors: Katie D. White, Riichiro Abe, Michael Ardern-Jones, Thomas Beachkofsky, Charles Bouchard, Bruce Carleton, James Chodosh, Ricardo Cibotti, Robert Davis, Joshua C. Denny, Roni P. Dodiuk-Gad, Elizabeth N. Ergen, Jennifer L. Goldman, James H. Holmes, Shuen Iu Hung, Mario E. Lacouture, Rannakoe J. Lehloenya, Simon Mallal, Teri A. Manolio, Robert G. Micheletti, Caroline M. Mitchell, Maja Mockenhaupt, David A. Ostrov, Rebecca Pavlos, Munir Pirmohamed, Elena Pope, Alec Redwood, Misha Rosenbach, Michael D. Rosenblum, Jean Claude Roujeau, Arturo P. Saavedra, Hajirah N. Saeed, Jeffery P. Struewing, Hirohiko Sueki, Chonlaphat Sukasem, Cynthia Sung, Jason A. Trubiano, Jessica Weintraub, Lisa M. Wheatley, Kristina B. Williams, Brandon Worley, Wen Hung Chung, Neil H. Shear, Elizabeth J. Phillips
• Other Authors: Duke-NUS Medical School Singapore
• Format: Review
• Published: 2019
• Subjects: Medicine
• Online Access: https://repository.li.mahidol.ac.th/handle/123456789/47258
• Institution: Mahidol University

© 2017 American Academy of Allergy, Asthma & Immunology Stevens-Johnson syndrome/toxic epidermal necrolysis (SJS/TEN) is a life-threatening, immunologically mediated, and usually drug-induced disease with a high burden to individuals, their families, and society with an annual incidence of 1 to 5 per 1,000,000. To effect significant reduction in short- and long-term morbidity and mortality, and advance clinical care and research, coordination of multiple medical, surgical, behavioral, and basic scientific disciplines is required. On March 2, 2017, an investigator-driven meeting was held immediately before the American Academy of Dermatology Annual meeting for the central purpose of assembling, for the first time in the United States, clinicians and scientists from multiple disciplines involved in SJS/TEN clinical care and basic science research. As a product of this meeting, this article summarizes the current state of knowledge and expert opinion related to SJS/TEN covering a broad spectrum of topics including epidemiology and pharmacogenomic networks; clinical management and complications; special populations such as pediatrics, the elderly, and pregnant women; regulatory issues and the electronic health record; new agents that cause SJS/TEN; pharmacogenomics and immunopathogenesis; and the patient perspective. Goals include the maintenance of a durable and productive multidisciplinary network that will significantly further scientific progress and translation into prevention, early diagnosis, and management of SJS/TEN.